Screener / SEC EDGAR /CIK 0001468328 /10-K filed Feb 24, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Home Health Care Services

Addus HomeCare Corp ADUS

Compare with peers Embed
FY2025 at a glance

Sales up 23.2%, free cash flow down to $103.8M

XBRL, from each 10-K
RevenueStatements
$1.4B from $1.2B in FY2024
FY2016FY2025
Net incomeStatements
$95.9M from $73.6M in FY2024
FY2016FY2025
Free cash flowStatements
$103.8M from $110.4M in FY2024
FY2016FY2025
EPS (diluted)Statements
$5.22 from $4.23 in FY2024
FY2016FY2025
Operating marginStatements
9.7% from 8.9% in FY2024
FY2016FY2025
Total debtStatements
$121.0M from $218.4M in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (40)
EPS (ttm)
6.01
Sales (ttm)
1.5B
Net income (ttm)
111.1M
Sales growth
+23.2%
EPS growth
+23.4%
Sales Q/Q
+7.0%
Free cash flow
144.2M
Gross margin
32.3%
Oper. margin
10.3%
Net margin
7.4%
FCF margin
9.6%
ROE
9.4%
ROA
7.7%
R&D / sales
-
Dividend
-
Debt/Eq
0.02
Curr. ratio
1.64
Cash
-
Op. cash flow (ttm)
152.1M
EBITDA
155.0M
EBITDA margin
10.9%
Quick ratio
1.64
Interest cover
10.18
ROIC
8.7%
FCF after stock pay
87.4M
Debt / FCF (years)
0.21
Goodwill / assets
69.3%
Oper. margin low 5y
7.2%
Tax rate
24.7%
Stock pay / sales
1.2%
Shares out.
18.6M
Shares Y/Y
+5.8%
Book / share
63.31
Sales / share
80.60
Asset turnover
1.04
Days sales out.
39
Sales 3Y CAGR
+14.4%
Sales 5Y CAGR
+13.2%
EPS 3Y CAGR
+22.5%
EPS 5Y CAGR
+20.2%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 1.4B +15.1% a year Net income 95.9M +25.8% a year
FY2016 revenue 400.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-19-008098 FY2016 net income 12.2M · NetIncomeLoss, 0001564590-19-008098 400.9M FY2016 FY2017 revenue 426.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-20-038909 FY2017 net income 12.0M · NetIncomeLoss, 0001564590-20-038909 426.0M FY2017 FY2018 revenue 516.6M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-21-009604 FY2018 net income 16.4M · NetIncomeLoss, 0001564590-21-009604 516.6M FY2018 FY2019 revenue 648.8M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-22-007171 FY2019 net income 25.2M · NetIncomeLoss, 0001564590-22-007171 648.8M FY2019 FY2020 revenue 764.8M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-23-005160 FY2020 net income 33.1M · NetIncomeLoss, 0000950170-23-005160 764.8M FY2020 FY2021 revenue 864.5M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-24-021284 FY2021 net income 45.1M · NetIncomeLoss, 0000950170-24-021284 864.5M FY2021 FY2022 revenue 951.1M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-25-026747 FY2022 net income 46.0M · NetIncomeLoss, 0000950170-25-026747 951.1M FY2022 FY2023 revenue 1.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001437749-26-005352 FY2023 net income 62.5M · NetIncomeLoss, 0001437749-26-005352 1.1B FY2023 FY2024 revenue 1.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001437749-26-005352 FY2024 net income 73.6M · NetIncomeLoss, 0001437749-26-005352 1.2B FY2024 FY2025 revenue 1.4B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001437749-26-005352 FY2025 net income 95.9M · NetIncomeLoss, 0001437749-26-005352 1.4B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

From the same starting line, FY2016 to FY2025

Revenue, net income and free cash flow, each set to 100 in FY2016. What happened, from the 10-Ks. Not a forecast.

FY2016 = 100
200 400 600 800 100 Revenue: $400.9M in FY2016, $1.4B in FY2025 REVENUE $1.4B · 3.5x Net income: $12.2M in FY2016, $95.9M in FY2025 NET INCOME $95.9M · 7.9x FY2016 = 100FY2021FY2025
Revenue 3.5x $400.9M to $1.4B
Net income 7.9x $12.2M to $95.9M

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Earnings per share +17.5% a year FY2015 $1.04 to FY2025 $5.22, 10 years
Book value per share +16.6% a year FY2015 $12.65 to FY2025 $59.01, 10 years
Free cash flow per share +42.0% a year FY2015 $0.17 to FY2025 $5.64, 10 years
200 400 100 EPS: $1.04 in FY2015, $5.22 in FY2025 EPS $5.22 · 5.0x Book value / share: $12.65 in FY2015, $59.01 in FY2025 BOOK VALUE / SHARE $59.01 · 4.7x FY2015 = 100FY2020FY2025

Each line is set to 100 in FY2015, so a line at 200 has doubled. What was filed, not a forecast. A line is left out when it is not above zero in every year.

Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $5.22$59.01$5.64
Dec 31, 2024 $4.23$55.84$6.35
Dec 31, 2023 $3.83$43.33$6.30
Dec 31, 2022 $2.84$39.15$5.98
Dec 31, 2021 $2.81$35.75$2.17
Dec 31, 2020 $2.08$32.51$6.43
Dec 31, 2019 $1.77$33.38$0.52
Dec 31, 2018 $1.33$21.68$2.25
Dec 31, 2017 $1.03$14.66$4.23
Dec 31, 2016 $1.07$13.63-$0.22
Dec 31, 2015 $1.04$12.65$0.17

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $269.5M
  • − All liabilities $352.0M
  • = Net current asset value -$82.5M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $1.1B
  • − Goodwill $996.7M
  • − Other intangible assets $102.4M
  • = Tangible book value -$13.8M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

ADUS against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+23.2%33rd of 155 · median +10.5%
Net margin
-4.1%15.3%
7.4%74th of 154 · median 6.8%
Return on equity
-5.2%18.5%
9.4%70th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
9.6%75th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
0.023rd of 108 · median 0.69
ADUS and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
ADUS Addus HomeCare Corp$1.5B +23.2%32.3%7.4%9.4%9.6%0.02
LNTH Lantheus Holdings, Inc.$1.6B +0.5%61.3%17.3%19.9%-0.42
PEN Penumbra Inc$1.6B +17.5%68.0%10.1%9.9%12.8%-
INSM INSMED Inc$1.5B +66.7%84.4%-39.9%-83.4%-41.3%0.75
LIVN LivaNova PLC$1.5B +10.7%67.8%13.0%14.3%8.6%0.22
MDGL Madrigal Pharmaceuticals, Inc.$1.4B +432%--10.9%-24.8%-11.8%0.54
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by segment

From $864.5M of sales to $45.1M of profit FY2021

  • Personal Care $685.9M
  • Hospice $152.3M
  • Home Health $26.4M
Revenue to Gross profit: $269.8MRevenue to Cost of revenue: $594.7MGross profit to Operating profit: $65.9MGross profit to Operating expenses: $203.9MOperating profit to Net profit: $45.1MOperating profit to Tax & other: $20.8M Revenue: $864.5M REVENUE $864.5M +13% Y/Y Gross profit: $269.8M · 31% margin GROSS PROFIT $269.8M 31% margin · +19% Y/Y Cost of revenue: $594.7M · 69% of revenue COST OF REVENUE $594.7M 69% of revenue Operating profit: $65.9M · 8% margin OPERATING PROFIT $65.9M 8% margin · +48% Y/Y Operating expenses: $203.9M · 24% of revenue OPERATING EXPENSES $203.9M 24% of revenue Net profit: $45.1M · 5% margin NET PROFIT $45.1M 5% margin · +36% Y/Y Tax & other: $20.8M · 2% of revenue TAX & OTHER $20.8M 2% of revenue

From $951.1M of sales to $46.0M of profit FY2022

  • Personal Care $706.5M
  • Hospice $201.8M
  • Home Health $42.8M
Revenue to Gross profit: $299.7MRevenue to Cost of revenue: $651.4MGross profit to Operating profit: $68.7MGross profit to Operating expenses: $231.0MOperating profit to Net profit: $46.0MOperating profit to Tax & other: $22.7M Revenue: $951.1M REVENUE $951.1M +10% Y/Y Gross profit: $299.7M · 32% margin GROSS PROFIT $299.7M 32% margin · +11% Y/Y Cost of revenue: $651.4M · 68% of revenue COST OF REVENUE $651.4M 68% of revenue Operating profit: $68.7M · 7% margin OPERATING PROFIT $68.7M 7% margin · +4% Y/Y Operating expenses: $231.0M · 24% of revenue OPERATING EXPENSES $231.0M 24% of revenue Net profit: $46.0M · 5% margin NET PROFIT $46.0M 5% margin · +2% Y/Y Tax & other: $22.7M · 2% of revenue TAX & OTHER $22.7M 2% of revenue

From $1.1B of sales to $62.5M of profit FY2023

  • Personal Care $794.7M
  • Hospice $207.2M
  • Home Health $56.8M
Revenue to Gross profit: $339.9MRevenue to Cost of revenue: $718.8MGross profit to Operating profit: $91.0MGross profit to Operating expenses: $248.9MOperating profit to Net profit: $62.5MOperating profit to Tax & other: $28.4M Revenue: $1.1B REVENUE $1.1B +11% Y/Y Gross profit: $339.9M · 32% margin GROSS PROFIT $339.9M 32% margin · +13% Y/Y Cost of revenue: $718.8M · 68% of revenue COST OF REVENUE $718.8M 68% of revenue Operating profit: $91.0M · 9% margin OPERATING PROFIT $91.0M 9% margin · +32% Y/Y Operating expenses: $248.9M · 24% of revenue OPERATING EXPENSES $248.9M 24% of revenue Net profit: $62.5M · 6% margin NET PROFIT $62.5M 6% margin · +36% Y/Y Tax & other: $28.4M · 3% of revenue TAX & OTHER $28.4M 3% of revenue

From $1.2B of sales to $73.6M of profit FY2024

  • Personal Care $856.6M
  • Hospice $228.2M
  • Home Health $69.8M
Revenue to Gross profit: $375.0MRevenue to Cost of revenue: $779.6MGross profit to Operating profit: $102.7MGross profit to Operating expenses: $272.3MOperating profit to Net profit: $73.6MOperating profit to Tax & other: $29.1M Revenue: $1.2B REVENUE $1.2B +9% Y/Y Gross profit: $375.0M · 32% margin GROSS PROFIT $375.0M 32% margin · +10% Y/Y Cost of revenue: $779.6M · 68% of revenue COST OF REVENUE $779.6M 68% of revenue Operating profit: $102.7M · 9% margin OPERATING PROFIT $102.7M 9% margin · +13% Y/Y Operating expenses: $272.3M · 24% of revenue OPERATING EXPENSES $272.3M 24% of revenue Net profit: $73.6M · 6% margin NET PROFIT $73.6M 6% margin · +18% Y/Y Tax & other: $29.1M · 3% of revenue TAX & OTHER $29.1M 3% of revenue

From $1.4B of sales to $95.9M of profit FY2025

  • Personal Care $1.1B
  • Hospice $262.5M
  • Home Health $70.8M
Revenue to Gross profit: $461.9MRevenue to Cost of revenue: $960.7MGross profit to Operating profit: $138.6MGross profit to Operating expenses: $323.3MOperating profit to Net profit: $95.9MOperating profit to Tax & other: $42.7M Revenue: $1.4B REVENUE $1.4B +23% Y/Y Gross profit: $461.9M · 32% margin GROSS PROFIT $461.9M 32% margin · +23% Y/Y Cost of revenue: $960.7M · 68% of revenue COST OF REVENUE $960.7M 68% of revenue Operating profit: $138.6M · 10% margin OPERATING PROFIT $138.6M 10% margin · +35% Y/Y Operating expenses: $323.3M · 23% of revenue OPERATING EXPENSES $323.3M 23% of revenue Net profit: $95.9M · 7% margin NET PROFIT $95.9M 7% margin · +30% Y/Y Tax & other: $42.7M · 3% of revenue TAX & OTHER $42.7M 3% of revenue

Where each $100 of sales went

FY2021
FY2022
FY2023
FY2024
FY2025
  • Cost of revenue
  • Sales, admin & other
  • Tax & other
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity 8.8% FY2020: 6.4% net income ÷ equity
Net margin 6.7% FY2020: 4.3% profit per $ of sales: 95.9M ÷ 1.4B
Asset turnover 0.99× FY2020: 0.86× sales per $ of assets: 1.4B ÷ 1.4B
Leverage 1.32× FY2020: 1.72× assets per $ of equity: 1.4B ÷ 1.1B

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin above the peer median
    7.4% vs 6.8%
  • Gross margin up over 5 years
    29.6% → 32.5%
  • Return on equity below 15%
    9.4%
  • A profit in every one of 10 years
Net margin, FY2016 to FY2025: 3.0% to 6.7%

Balance sheet

  • Interest covered more than 5 times
    Operating income is 10.2× interest expense
  • Debt smaller than equity
    Debt / equity 0.02 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 1.64
Debt / equity at each year end, FY2016 to FY2025: 0.16 to 0.11

Cash and shareholders

  • Free cash flow positive in 9 of 10 years
    $103.8M last year
  • Share count up over 5 years
    +15.3%
  • Cash from operations above net income
    $111.5M vs $95.9M
Free cash flow, FY2016 to FY2025: -2.5M to 103.8M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

ADUS's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue1.4B
FY2016: 400.9MFY2017: 426.0MFY2018: 516.6MFY2019: 648.8MFY2020: 764.8MFY2021: 864.5MFY2022: 951.1MFY2023: 1.1BFY2024: 1.2BFY2025: 1.4B FY2017FY2019FY2021FY2023FY2025
Net income95.9M
FY2016: 12.2MFY2017: 12.0MFY2018: 16.4MFY2019: 25.2MFY2020: 33.1MFY2021: 45.1MFY2022: 46.0MFY2023: 62.5MFY2024: 73.6MFY2025: 95.9M FY2017FY2019FY2021FY2023FY2025
Free cash flow103.8M
FY2016: -2.5MFY2017: 49.2MFY2018: 27.9MFY2019: 7.4MFY2020: 102.6MFY2021: 34.8MFY2022: 96.8MFY2023: 102.8MFY2024: 110.4MFY2025: 103.8M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay87.4M
FY2016: -3.5MFY2017: 46.6MFY2018: 23.7MFY2019: 1.6MFY2020: 96.6MFY2021: 25.4MFY2022: 86.2MFY2023: 92.5MFY2024: 99.2MFY2025: 87.4M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)5.22
FY2016: 1.07FY2017: 1.03FY2018: 1.33FY2019: 1.77FY2020: 2.08FY2021: 2.81FY2022: 2.84FY2023: 3.83FY2024: 4.23FY2025: 5.22 FY2017FY2019FY2021FY2023FY2025
Diluted shares18.4M
FY2016: 11.3MFY2017: 11.6MFY2018: 12.4MFY2019: 14.2MFY2020: 16.0MFY2021: 16.1MFY2022: 16.2MFY2023: 16.3MFY2024: 17.4MFY2025: 18.4M FY2017FY2019FY2021FY2023FY2025

Revenue by business segment

year to Dec 31, 2025
RevenueSharevs year before
Personal Care 1.1B76.6% +27.2%
Hospice 262.5M18.5% +15.1%
Home Health 70.8M5.0% +1.4%

10-K 0001437749-26-005352, segment and revenue notes (XBRL).

Revenue by business segment, 5 years

from the segment notes of the last 3 10-Ks
FY2021FY2022FY2023FY2024FY2025
Personal Care685.9M706.5M794.7M856.6M1.1B
Hospice152.3M201.8M207.2M228.2M262.5M
Home Health26.4M42.8M56.8M69.8M70.8M
Sum of segments864.5M951.1M1.1B1.2B1.4B

Operating income by business segment, 5 years

from the segment notes of the last 3 10-Ks
FY2021FY2022FY2023FY2024FY2025
Personal Care122.3M125.4M157.5M174.2M207.2M
Hospice42.4M51.1M44.9M51.9M67.4M
Home Health3.2M2.8M7.0M7.9M12.5M

Revenue and operating income by business segment, as each 10-K reports them in its segment note (XBRL). Each year comes from the newest 10-K that reports it, so a year the company later recast shows the recast number; click a number to open that 10-K. Rows without a number were not reported as a separate segment that year. "Corporate and other" and "All other" are the 10-K's own lines for what is outside the segments.

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue400.9M426.0M516.6M648.8M764.8M864.5M951.1M1.1B1.2B1.4B
Cost of revenue294.6M310.1M379.8M469.6M538.5M594.7M651.4M718.8M779.6M960.7M
Gross profit106.3M115.9M136.8M179.2M226.2M269.8M299.7M339.9M375.0M461.9M
SG&A76.8M76.9M105.3M133.9M169.7M189.4M216.9M234.8M258.8M306.8M
Operating income15.5M25.3M22.8M34.8M44.5M65.9M68.7M91.0M102.7M138.6M
Interest expense2.3M4.5M5.0M3.1M3.2M5.8M8.9M11.1M7.7M13.6M
Pretax income16.2M21.1M20.4M33.2M41.9M60.4M60.2M81.3M99.4M127.4M
Income tax4.1M9.3M4.1M7.4M8.8M15.3M14.1M18.8M25.8M31.5M
Net income12.2M12.0M16.4M25.2M33.1M45.1M46.0M62.5M73.6M95.9M
EPS (diluted)1.071.031.331.772.082.812.843.834.235.22
Diluted shares11.3M11.6M12.4M14.2M16.0M16.1M16.2M16.3M17.4M18.4M
Depreciation & amortization6.6M6.7M8.6M10.6M12.1M14.5M14.1M14.1M13.5M16.4M
EBITDA22.1M31.9M31.5M45.3M56.6M80.4M82.8M105.1M116.2M155.0M
Gross margin26.5%27.2%26.5%27.6%29.6%31.2%31.5%32.1%32.5%32.5%
Operating margin3.9%5.9%4.4%5.4%5.8%7.6%7.2%8.6%8.9%9.7%
Net margin3.0%2.8%3.2%3.9%4.3%5.2%4.8%5.9%6.4%6.7%
Revenue growth-+6.3%+21.3%+25.6%+17.9%+13.0%+10.0%+11.3%+9.1%+23.2%
EPS growth+2.9%-3.7%+29.1%+33.1%+17.5%+35.1%+1.1%+34.9%+10.4%+23.4%

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-743K52.8M33.2M12.0M109.4M39.5M105.1M112.2M116.4M111.5M
Capital spending1.7M3.6M5.3M4.6M6.8M4.6M8.3M9.5M6.0M7.7M
Free cash flow-2.5M49.2M27.9M7.4M102.6M34.8M96.8M102.8M110.4M103.8M
Stock-based pay (added back)1.1M2.6M4.1M5.8M6.0M9.4M10.6M10.3M11.2M16.4M
Free cash flow after stock pay-3.5M46.6M23.7M1.6M96.6M25.4M86.2M92.5M99.2M87.4M
Acquisitions20.0M24.4M62.4M184.1M207.7M37.4M98.3M109.8M353.9M-
Debt raised25.0M45.0M60.4M19.6M------
Debt repaid938K24.1M--------
Investing cash flow-21.7M-24.3M-67.8M-188.7M-214.2M-42.0M-106.6M-119.2M-354.6M-32.5M
Financing cash flow26.4M17.2M51.2M218.0M138.2M26.3M-87.5M-8.2M272.3M-96.3M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)1.1M2.6M4.1M5.8M6.0M9.4M10.6M10.3M11.2M16.4M
Stock-based pay / revenue0.3%0.6%0.8%0.9%0.8%1.1%1.1%1.0%1.0%1.2%
Operating lease cost---7.2M9.2M11.2M11.4M13.0M13.4M14.7M
Operating lease cash paid---7.6M8.8M11.3M13.0M14.4M14.8M16.8M
Finance lease principal paid-1.4M1.0M63K22K-----
Right-of-use assets---21.1M38.0M36.0M39.0M45.4M47.3M43.7M
Operating lease liabilities---21.5M44.8M42.6M46.3M51.0M54.7M50.4M
Finance lease liabilities--81K21K------

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ADUS/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.